Brief: Maxcyte Says Enters Strategic Platform License With TG Therapeutics
12/02/2025 07:18
Feb 12 (Reuters) - MaxCyte Inc MXCT.O :
* MAXCYTE, INC. MAXCYTE, INC. - MXCR - STRATEGIC PLATFORM
LICENSE
WITH TG THERAPEUTICS
* MAXCYTE INC - ENTERS STRATEGIC PLATFORM LICENSE WITH TG
THERAPEUTICS
* MAXCYTE INC - TG THERAPEUTICS OBTAINS RIGHTS TO USE
MAXCYTE
TECHNOLOGY
Source text: ID:nRSL7610Wa
Further company coverage: MXCT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on MaxCyte
See all newsMaxCyte Q1 revenue falls
Brief: Maxcyte Appoints Parmeet Ahuja As Chief Financial Officer
Brief: Maxcyte Announces Preliminary Unaudited Fourth Quarter And Full Year 2025 Financial Results
MaxCyte Q3 revenue falls 16% hurt by lower sales in instruments
Brief: MaxCyte Announces Planned CFO Transition In 2026